Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler)

Bone Marrow Transplantation

Volumn 35, Issue 3, 2005, Pages 265-269

  Grigull, Lorenz ^a   Beilken, A ^a   Schrappe, M ^a   Das, A ^a   Luecke, T ^a   Sander, A ^a   Stanulla, M ^a   Rehe, K ^a   Sauer, M ^a   Schmid, H ^a   Welte, K ^a   Lukacs, Z ^b   Gal, A ^b   Sykora, K W ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CD34+ selection; Donor lymphocyte infusion; Fludarabine; Mucopolysaccharidosis

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOSPORIN A; DERMATAN; FLUDARABINE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HLA ANTIGEN; LEVO IDURONIDASE; MELPHALAN; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CD34 SELECTION; CLINICAL ARTICLE; DEATH; DONOR; FEASIBILITY STUDY; GLYCOSAMINOGLYCAN METABOLISM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; HURLER SYNDROME; INBORN ERROR OF METABOLISM; INFANT; LYMPHOCYTE TRANSFUSION; PERIPHERAL BLOOD STEM CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; URINALYSIS;

ANTIGENS, CD34; ANTILYMPHOCYTE SERUM; BUSULFAN; CHILD, PRESCHOOL; GRAFT SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LYMPHOCYTE TRANSFUSION; MUCOPOLYSACCHARIDOSIS I; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 13944263629     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704786     Document Type: Article

References (32)

1. Beck M. Variable clinical presentation in lysosomal storage disorders. J Inherit Metab Dis 2001; 24 (Suppl 2): 47-51.
2. Peters C, Balthazor M, Shapiro EG et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87: 4894-4902.
3. Peters C, Shapiro EG, Anderson J et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 1998; 91: 2601-2608.
4. Peters C, Shapiro EG, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant 1998; 2: 250-253.
5. Grewal SS, Krivit W, Defor TE et al. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant 2002; 29: 491-496.
6. McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
7. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175-188.
8. Keating MJ, O'Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
9. Nieto Y, Vaughan WP. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 2004; 33: 259-269.
10. Schmidt J, Fleissner S, Heimann-Weitschat I et al. Effect of corticosteroids, cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets. Immunopharmacology 1994; 27: 173-179.
11. Scott HS, Bunge S, Gal A et al. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 1995; 6: 288-302.
12. Yogalingam G, Guo XH, Muller VJ et al. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat 2004; 24: 199-207.
13. Guffon N, Souillet G, Maire I et al. Follow-up of nine patients with Hurler syndrome after bone marrow transplantation. J Pediatr 1998; 133: 119-125.
14. Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-1034.
15. Jacobson P, Park JJ, Defor TE et al. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation. Bone Marrow Transplant 2001; 27: 855-861.
16. Krivit W, Aubourg P, Shapiro E, Peters C. Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr Opin Hematol 1999; 6: 377-382.
17. Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
18. Dalle JH, Wall D, Theoret Y et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 2003; 32: 647-651.
19. Nguyen L, Fuller D, Lennon S et al. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33: 979-987.
20. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6 1768-1782.
21. Singhal S, Powles R, Treleaven J et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: allo-engraftment with potential preservation of fertility in women. Bone Marrow Transplant 1996; 18: 1049-1055.
22. Taha IA, Ahmad RA, Rogers DW et al. Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol 1983; 10: 212-216.
23. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
24. Staba SL, Escolar ML, Poe M et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004; 350: 1960-1969.
25. Ho VT, Weller E, Lee SJ et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 223-229.
26. Ritchie DS, Seymour JF, Roberts AW et al. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001; 28: 101-103.
27. Reisner Y, Martelli MF. Tolerance induction by 'megadose' transplants of CD34+ stem cells: a new option for leukemia patients without an HLA-matched donor. Curr Opin Immunol 2000; 12: 536-541.
28. Lang P, Klingebiel T, Bader P et al. Transplantation of highly purified peripheral-blood CD34+ progenitor cells from related and unrelated donors in children with nonmalignant diseases. Bone Marrow Transplant 2004; 33: 25-32.
29. Kremens B, Basu O, Peceny R et al. Allogeneic CD34+-selected peripheral stem cell transplantation from parental donors in children with non-malignant diseases. Bone Marrow Transplant 2002; 29: 9-13.
30. Bader P, Klingebiel T, Schaudt A et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
31. Bader P, Kreyenberg H, Hoelle W et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004; 33: 815-821.
32. Woodard P, Cunningham JM, Benaim E et al. Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant 2004; 33: 411-418.